Evidence map›Paper›PMID 41746282›Full record

ArticleBioinformatics (Oxford, England)2026

Differential cell signaling testing for cell-cell communication inference from single-cell data by dominoSignal.

Jacob T Mitchell, Orian Stapleton, Kavita Krishnan, Sushma Nagaraj, Dmitrijs Lvovs, Christopher Cherry, Amanda Poissonnier, Wesley Horton, Andrew Adey, Varun Rao and 8 more

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jacob T MitchellDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, United States.ORCID 0000-0002-5370-9692
Orian StapletonDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, United States.
Kavita KrishnanDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, United States.
Sushma NagarajDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, United States.
Dmitrijs LvovsInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, United States.
Christopher CherryDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, United States.
Amanda PoissonnierDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR 97239, United States.
Wesley HortonDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR 97239, United States.
Andrew AdeyDepartment of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR 97239, United States.
Varun RaoInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, United States.
Amanda HuffDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, United States.
Jacquelyn W ZimmermanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, United States.
Luciane T KagoharaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, United States.
Neeha ZaidiDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, United States.
Lisa M CoussensDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR 97239, United States.
Elizabeth M JaffeeDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, United States.
Jennifer H ElisseeffDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, United States.
Elana J FertigDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21205, United States.

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Transforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 2021 to 2025
$12.7M
Tumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic CancerU54CA274371 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Elana Fertig · 2022 to 2026
$9.5M
JHU-Mayo-NIA Murine Senescence Mapping Program (JMN-MSMP)U54AG079779 · NIA · JOHNS HOPKINS UNIVERSITY · PI JENNIFER H ELISSEEFF · 2022 to 2026
$6.4M
Biomaterials-directed regenerative immunotherapiesDP1AR076959 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ELISSEEFF, JENNIFER H · 2019 to 2023
$5.7M
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9M
Develop BCL-xL proteolysis targeting chimeras as safer and better senolyticsR01AG063801 · NIA · UNIVERSITY OF FLORIDA · PI ELISSEEFF, JENNIFER H, ZHENG, GUANGRONG · 2019 to 2023
$2.6M
Informing mechanistic rules of agent-based models with single-cell multi-omicsU24CA284156 · NCI · TRUSTEES OF INDIANA UNIVERSITY · PI Elana Fertig, Paul T Macklin · 2024 to 2026
$2.3M
Single-cell and imaging data integration software to spatially resolve the tumor microenvironmentU01CA253403 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2020 to 2022
$1.2M
Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic CancerK08CA248624 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZAIDI, NEEHA · 2021 to 2025
$1.1M
Investigation of Immunotherapy-induced Alterations to Cellular Communication Networks in Pancreatic Ductal AdenocarcinomaF31CA284525 · NCI · JOHNS HOPKINS UNIVERSITY · PI MITCHELL, JACOB THOMAS · 2024 to 2024
$42k
ASCO Career Development Award (to NZ), the Lamfrom Endowed Chair in Basic ResearchBloomberg Kimmel Institute for Cancer ImmunotherapyDepartment of Defense Breast Cancer Research Program Breakthrough Fellowship BC190819Department of Defense Breast Cancer Research Program Breakthrough Fellowship W81XWH-20-1-0007Knight Pilot AwardLustgarten FoundationNational Foundation for Cancer ResearchNCI NIH HHS U24 CA284156NCI NIH HHS U54 CA274371NIA NIH HHS U54 AG079779NIH HHS 5T32GM07814NIH HHS DP1AR076959NIH HHS F31CA284525NIH HHS K08CA248624NIH HHS P01CA247886NIH HHS P30CA069533NIH HHS R01AG063801NIH HHS U01CA224012NIH HHS U01CA253403NIH HHS U24CA284156NIH HHS U54AG079779NIH HHS U54CA274371OHSU Brenden-Colsson Center for Pancreatic CareSusan G Komen Foundation
6 · The paper itself

Abstract

motivationAlgorithms for ligand-receptor network inference have emerged as commonly used tools to estimate cell-cell communication from reference single-cell data. Many studies employ these algorithms to compare signaling between conditions and lack methods to statistically identify signals that are significantly different. We previously developed the cell communication inference algorithm Domino, which considers ligand and receptor gene expression in association with downstream transcription factor activity scoring. We developed the dominoSignal software to innovate upon Domino and extend its functionality to test statistically differential cellular signaling.

resultsThis new functionality includes the compilation of active signals as linkages from multiple subjects in a single-cell data set and testing condition-dependent signaling linkage. The software is applicable for analysis of single-cell data sets with multiple subjects as biological replicates as well as with bootstrapped replicates from data sets with few or pooled subjects. We use simulation studies to benchmark the number of subjects in compared groups and cells within an annotated cell type sufficient to accurately identify differential linkages. We demonstrate the application of the Differential Cell Signaling Test (DCST) in the dominoSignal software to investigate consequences of cancer cell phenotypes and immunotherapy on cell-cell communication in tumor microenvironments. These applications in cancer studies demonstrate the ability of differential cell signaling analysis to infer changes to cell communication networks from therapeutic or experimental perturbations, which is broadly applicable across biological systems. AVAILABILITY: dominoSignal is available through Bioconductor at https://www.bioconductor.org/packages/release/bioc/html/dominoSignal.html.

Indexed as

Cell CommunicationComputational BiologySignal TransductionSingle-Cell AnalysisSoftwareAlgorithmsHumans

Identifiers

PMID41746282
PMCPMC12998610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.